Charles Rosenberg, a historian of medicine and science, observed that viral outbreaks often unfold like a play in three acts. Act 1 is to ignore the mounting threat until it can’t be avoided. Act 2 is a call to arms (citizens demanding an explanation). And Act 3 – the one we are in now – is the response. Act 3, according to Rosenberg, can be “as disruptive as the disease itself.” The potential disruptions from Act 3 of COVID-19 have significant short- and long-term implications. Our proactive responsiveness to those disruptions can help drive success.
David Fajgenbaum’s life changed forever one summer day in 2010. After experiencing fatigue, his liver, kidneys, bone marrow, heart, and lungs suddenly began to shut down. He was admitted to the intensive care unit where doctors found that he had a retinal hemorrhage that left him blind in his left eye. David drifted in and out of consciousness, was put on a feeding tube, and received blood transfusions. In weeks, the 26-year-old medical student sharply deteriorated and was given last rites.
Rare diseases affect more than 30 million Americans. According to the FDA, a rare disease is defined as a disease or condition that has a prevalence of fewer than 200,000 affected individuals in the United States. An orphan product is a drug, biologic, device or medical food used for the prevention, diagnosis, or treatment of a rare disease.
Despite advances in technology and our understanding of the genetic and molecular underpinnings of cancer, making a meaningful impact on the survival and quality of life of patients with cancer remains a significant challenge. In fact, a recent review revealed that, among 59 cancer drugs approved by the U.S. Food and Drug Administration based on the surrogate endpoint of response rate, only six showed overall survival benefit.
Top 10 Pipelines To Watch
Acquisitions, Analysts, Annual Reports, Blockbuster Deals, Blockbusters, Business, Clinical Trials, Deals, Dengue, Department of Health and Human Services (HHS), Dermatology, Diffuse Large B-Cell Lymphoma (DLBCL), EMA, European Commission, European Medicines Agency (EMA), FDA, FDA/Regulatory, February 2020, Future Blockbusters, Hemophilia A, Hospital-Acquired Bacterial Pneumonia, Issue Archives, Licensing, Natural Killer Cells (NK Cells), New Drug Applications, New Molecular Entities, NMEs, Oncology, Potential Blockbusters, Priority Review, Priority Review Status, Product Pipelines, R&D, Rare Diseases, Senate Panel, Special Reports, Top 10 Pipelines, Top 10 Pipelines To Watch, VaccinesAs pharma companies bolster their pipelines via multibillion-dollar acquisitions, drug manufacturers continue to heavily invest in the oncology space.
Oncology Innovation
Annual Reports, Antibody-Drug Conjugates (ADCs), Biomarkers, Bladder Cancer, BRCA mutation, Breast Cancer, Clinical Trials, FDA/Regulatory, February 2020, Issue Archives, Non-Small Cell Lung Cancer (NSCLC), Oncology, Pancreatic Cancer, R&D, Targeted Therapies, Thyroid Cancer, Top 10 Pipelines To WatchOncology is one of the most exciting areas in healthcare, as novel therapies continue to emerge that move forward our molecular understanding of the disease and offer effective treatment advances. This Q&A explores oncology innovation with Kantar’s Stephanie Hawthorne, Vice President of Oncology and Specialty Therapeutics.
MedAdNews spoke to Bill Dreitlein, Senior Director, Pipeline & Drug Surveillance at OptumRx, about the state of the industry’s prescription drug pipeline and what enticing prospects will soon emerge.
Executive management from the 2019 Manny Award agency and network winners & finalists provide expert insight on healthcare industry topics and predictions.
If there was one song that could be the pharma industry’s anthem during 2018-2019, it would be the David Bowie/Freddie Mercury hit “Under Pressure.” With the Trump administration’s and Congress’ efforts to reign in drug prices, pharma executives have a lot to keep them up at night.
Top 10 Pipelines To Watch: 2019 Annual Report
Analysts, Ankylosing Spondylitis (AS), Annual Reports, Antiretroviral Drugs, Atopic Dermatitis (Eczema), Autoimmune Diseases, B Cells, Big Pharma, Biologics, Biopharma, Biotechnology, Blockbusters, BRCA Gene, BRCA mutation, Breakthrough Therapy Designation, Business, Cancer, CAR-T Therapy, Cells, Chemotherapy, Clinical Data, Clinical Trials, Collaborations, Crohn's Disease, Cystic Fibrosis, Drug Discovery, EU, European Medicines Agency (EMA), Fast Track Designation, FDA, FDA/Regulatory, February 2019, Future Blockbusters, Gene Editing, Generalized Myasthenia Gravis (gMG), Genomics, HIV, Human Genome, Immune Cells, Immune System, Immune-Mediated Diseases, Immunotherapy, Inflammatory Diseases, Injectables, Innovation, Integrase strand transfer inhibitors, Issue Archives, Japan, M&A, Med Ad News, Monoclonal Antibodies, Multiple myeloma, Neoantigens, Neurology, Neuromyelitis Optica Spectrum Disorder (NMOSD), New Drug Applications, Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), Non-Small Cell Lung Cancer (NSCLC), Nonalcoholic Steatohepatitis (NASH), Nuclear Medicine, Oncology, Orphan Drug Designation, Paroxysmal Nocturnal Hemoglobinuria (PNH), Precision Medicine, Prescription Drug User Fee Act (PDUFA), Priority Medicines (PRIME) Designation, Priority Review Voucher, Product Pipelines, Proteins, Psoriatic Arthritis, R&D, Radioligands, Rare Disorders, Research, Rheumatoid Arthritis, RNA Interference (RNAi), Sickle Cell Disease, Small Molecules, Special Reports, T-Cells, Top 10 Pipelines, Top 10 Pipelines To Watch, Tumors, Ulcerative Colitis, Ultra Rare DiseasesThe return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.